Possibilities into Reality 


At Avalon, we believe that nurturing next generation healthcare solutions is the key to improving lives around the world

That is why, since our founding in 2013, we have been striving to develop and deliver new biomedical technologies. By leveraging our extensive network of investors and industry partners, we support innovators throughout the entire journey, from academic research, funding, to building the necessary commercialization framework for the final products to helping them achieve market success.

Headquartered in Hong Kong, the Avalon group is backed by the enormous economic potential of the Greater Bay Area (GBA), the fast-growing innovation and technology hub in Southern China that’s drawing start-ups from all over Asia. Here, our dedicated management team work tirelessly with the brightest minds in biomedical technology to develop first-in-class healthcare solutions that are of the highest quality and reliability. The four pillars of our business — public health and infection control, diagnostic platforms, medical device, and pharmaceutical — ensure that we are strategically focused on areas that can help address some of the world’s most pressing medical needs.



December 6, 2022
Avalon SteriTech Raises US$9M in Pre-Series A Funding to Accelerate its Overseas Expansion and Product Development
August 10, 2022
Emerging Viral Diagnostics Establishes Strategic Partnership with Shenzhou Space Biotechnology Group to Launch Clinical Trial in Mainland China cum Opening of the Manufacturing Facility at INNOPARK
May 11, 2022
Royale Home Announces Strategic Partnership with Avalon Biomedical Management
May 5, 2022
The Secretary for Innovation and Technology Visits Emerging Viral Diagnostics’ Production Site In MARS Centre
View All